Rosiglitazone-Associated Fractures in Type 2 Diabetes

Kahn, Steven E., Zinman, Bernard, Lachin, John M., Haffner, Steven M., Herman, William H., Holman, Rury R., Kravitz, Barbara G., Yu, Dahong, Heise, Mark A., Aftring, R. Paul, Viberti, Giancarlo, for the A Diabetes Outcome Progression Trial (ADOPT) Study Group·2008·Diabetes Care

DOI 10.2337/dc07-2270

Cited by (544)

Items 101–200 of 544

Diabetes and bone health: the relationship between diabetes and osteoporosis‐associated fractures
Salila Kurra, Ethel S. Siris · 2011 · Diabetes/Metabolism Research and Reviews
Impact of diabetes and its treatments on skeletal diseases
Wenbo Yan, Xin Li · 2013 · Frontiers of Medicine
Sex differences and correlates of poor glycaemic control in type 2 diabetes: a cross-sectional study in Brazil and Venezuela
Fernanda Gross Duarte, Sandra da Silva Moreira, Maria da Conceição Chagas de Almeida, Carlos Antônio de Souza Teles, Carine Sousa Andrade, Art L Reingold, Edson Duarte Moreira · 2019 · BMJ Open
Molecular determinants for the polarization of macrophage and osteoclast
Dengbao Yang, Yihong Wan · 2019 · Seminars in Immunopathology
3. Comprehensive Medical Evaluation and Assessment of Comorbidities
American Diabetes Association · 2016 · Diabetes Care
Participation of Women and Sex Analyses in Late-Phase Clinical Trials of New Molecular Entity Drugs and Biologics Approved by the FDA in 2007–2009
Rita Poon, Keshav Khanijow, Sphoorti Umarjee, Emmanuel O. Fadiran, Monica Yu, Lei Zhang, Ameeta Parekh · 2013 · Journal of Women s Health
Diabetes pharmacotherapy and effects on the musculoskeletal system
Evangelia Kalaitzoglou, John L. Fowlkes, Iuliana Ristea Popescu, Kathryn M. Thrailkill · 2018 · Diabetes/Metabolism Research and Reviews
Restoring Insulin Secretion (RISE): Design of Studies of β-Cell Preservation in Prediabetes and Early Type 2 Diabetes Across the Life Span
The RISE Consortium · 2013 · Diabetes Care
The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes
Nicola Napoli, Rocky Strollo, Angela Paladini, Silvia Briganti, Paolo Pozzilli, Sol Epstein · 2014 · International Journal of Endocrinology
Fat Infiltration of Muscle, Diabetes, and Clinical Fracture Risk in Older Adults
Anne L. Schafer, Eric Vittinghoff, Thomas Lang, Deborah E. Sellmeyer, Tamara B. Harris, Alka M. Kanaya, Elsa S. Strotmeyer, Peggy Mannen Cawthon, Steven Ron Cummings, Frances A. Tylavsky et al. · 2010 · The Journal of Clinical Endocrinology & Metabolism
PPARγ Antagonist Gleevec Improves Insulin Sensitivity and Promotes the Browning of White Adipose Tissue
Sun‐Sil Choi, Eun Sun Kim, Jieun Jung, David P. Marciano, Ala Jo, Ja Young Koo, Soo Youn Choi, Yong Ryoul Yang, Hyun‐Jun Jang, Eung‐Kyun Kim et al. · 2016 · Diabetes
Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode
Davide Capelli, Carmen Cerchia, Roberta Montanari, Fulvio Loiodice, Paolo Tortorella, Antonio Laghezza, Laura Cervoni, Giorgio Pochetti, Antonio Lavecchia · 2016 · Scientific Reports
Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus
John Paul Bilezikian, Robert G. Josse, Richard Eastell, Edward Michael Lewiecki, Colin G. Miller, Margaret J. Wooddell, Allison R. Northcutt, Barbara G. Kravitz, Gitanjali Paul, Alexander R. Cobitz et al. · 2013 · The Journal of Clinical Endocrinology & Metabolism
The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing
Jeshmi Jeyabalan, Benoı̂t Viollet, Peter Jonathan Smitham, S. A. Ellis, G. Zaman, Christophe Bardin, Allen E. Goodship, J. P. Roux, Pierre Meneton, Chantal Chenu · 2013 · Osteoporosis International
Relationship between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus
Ippei Kanazawa, Toru Yamaguchi, Masahiro Yamamoto, Toshitsugu Sugimoto · 2010 · Journal of Bone and Mineral Metabolism
Pharmacogenetics of Anti-Diabetes Drugs
Johanna Kay DiStefano, Richard M. Watanabe · 2010 · Pharmaceuticals
Bone health in diabetes: considerations for clinical management
Silvano Adami · 2009 · Current Medical Research and Opinion
PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption
L. A. Stechschulte, P. Czernik, Z. C. Rotter, F. N. Tausif, Cesar A. Corzo, David Marciano, Alice Asteian, Jie Zheng, J. Bruning, T. Kamenecka et al. · 2016 · EBioMedicine
Links among Obesity, Type 2 Diabetes Mellitus, and Osteoporosis: Bone as a Target
Monika Martiniaková, Roman Bíro, Noémi Pénzes, Anna Šarocká, Veronika Kováčová, Vladimíra Mondočková, Radoslav Omelka · 2024 · International Journal of Molecular Sciences
A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes
Daniel H. Solomon, Suzanne M. Cadarette, Niteesh K. Choudhry, Claire F. Canning, Raisa Levin, Til Stürmer‎ · 2009 · The Journal of Clinical Endocrinology & Metabolism
Thiazolidinediones Induce Osteocyte Apoptosis by a G Protein-coupled Receptor 40-dependent Mechanism
Aleksandra Mieczkowska, Michel Félix Baslé, Daniel Chappard, Guillaume Mabilleau · 2012 · Journal of Biological Chemistry
A call to incorporate the prevention and treatment of geriatric disorders in the management of diabetes in the elderly
Ulrich M. Vischer, Bernard Bauduceau, Isabelle Bourdel‐Marchasson, J F Blicklé, Thierry Constans, Anne Fagot‐Campagna, Edgar Kaloustian, V. Lassman-Vague, P. Lecomte, D. Simon et al. · 2009 · Diabetes & Metabolism
A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐na ï ve type 2 diabetes mellitus patients
João Lindolfo Cunha Borges, John Paul Bilezikian, Angela R. Jones-Leone, Andre Acusta, Phil Ambery, Antonio Nino, M. Bois Grosse, Lorraine A. Fitzpatrick, Alexander R. Cobitz · 2011 · Diabetes Obesity and Metabolism
Nuclear Receptors in Bone Physiology and Diseases
Yuuki Imai, Minyoung Youn, Kazuki Inoue, Ichiro Takada, Alexander Kouzmenko, Shigeaki Kato · 2013 · Physiological Reviews
Approach to the Patient with Prediabetes
Vanita R. Aroda, Robert E. Ratner · 2008 · The Journal of Clinical Endocrinology & Metabolism
A Novel Non-agonist Peroxisome Proliferator-activated Receptor γ (PPARγ) Ligand UHC1 Blocks PPARγ Phosphorylation by Cyclin-dependent Kinase 5 (CDK5) and Improves Insulin Sensitivity
Sun‐Sil Choi, Eun Sun Kim, Minseob Koh, Soojin Lee, Donghyun Lim, Yong Ryoul Yang, Hyun‐Jun Jang, Kyung‐Ah Seo, Sang‐Hyun Min, In Hee Lee et al. · 2014 · Journal of Biological Chemistry
Effects of TZD use and discontinuation on fracture rates in ACCORD bone study
Schwartz, Ann V., Chen, Haiying, Ambrosius, Walter T., Sood, Ajay, Josse, Robert G., Bonds, Denise E., Schnall, Adrian M., Vittinghoff, Eric, Bauer, Douglas C., Banerji, Mary Ann et al. · 2015 · The Journal of Clinical Endocrinology & Metabolism
Treating type 2 diabetes: how safe are current therapeutic agents?
Jacques Philippé, D. Raccah · 2009 · International Journal of Clinical Practice
Vertebral fractures in males with type 2 diabetes treated with rosiglitazone
Tatiana Mancini, Gherardo Mazziotti, Mauro Doga, Rita Carpinteri, Niksa Simetovic, Pier Paolo Vescovi, Andrea Giustina · 2009 · Bone
Thiazolidinediones and Fractures: Evidence from Translating Research into Action for Diabetes
Dori Bilik, Laura N. McEwen, Morton B. Brown, Nathan E. Pomeroy, Catherine Kim, Keiko Asao, Jesse C. Crosson, Obidiugwu Kenrik Duru, Assiamira M. Ferrara, Victoria C. Hsiao et al. · 2010 · The Journal of Clinical Endocrinology & Metabolism
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Zien Zhou, Meg Jardine, Vlado Perkovic, David Richard Matthews, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Mehul G. Desai, Richard Oh, Roger Simpson et al. · 2019 · Diabetologia
Ankaflavin: a natural novel PPARγ agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo
Bao‐Hong Lee, Wei-Hsuan Hsu, Yu-Ying Chang, Hsuan‐Fu Kuo, Ya-Wen Hsu, Tzu‐Ming Pan · 2012 · Free Radical Biology and Medicine
Thiazolidinediones and fracture risk in patients with Type 2 diabetes
D. J. Betteridge · 2010 · Diabetic Medicine
Adipocytes decrease Runx2 expression in osteoblastic cells: Roles of PPARγ and adiponectin
Li‐Fen Liu, Wen‐Jun Shen, Zhong Hua Zhang, Lijuan Wang, Fredric B. Kraemer · 2010 · Journal of Cellular Physiology
Control of Brown Adipose Tissue Glucose and Lipid Metabolism by PPARγ
William T. Festuccia, Pierre-Gilles Blanchard, Yves Deshaies · 2011 · Frontiers in Endocrinology
Patterns of Prescription Drug Use Before and After Fragility Fracture
Jeffrey C. Munson, Julie Bynum, John‐Erik Bell, Robert Victor Cantu, Christine M. McDonough, Qianfei Wang, Tor Devin Tosteson, Anna N.A. Tosteson · 2016 · JAMA Internal Medicine
The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta‐analysis of observational studies
Khemayanto Hidayat, Xuan Du, Mengjiao Wu, Bi‐Min Shi · 2019 · Obesity Reviews
Pharmacologic management of the older patient with type 2 diabetes mellitus
Joshua J. Neumiller, Stephen M. Setter · 2009 · The American Journal of Geriatric Pharmacotherapy
Differential effects of PPAR-{gamma} activation versus chemical or genetic reduction of DPP-4 activity on bone quality in mice.
K. Kyle, T. Willett, L. Baggio, D. Drucker, M. Grynpas · 2011 · Endocrinology
Distinct effects of pioglitazone and metformin on circulating sclerostin and biochemical markers of bone turnover in men with type 2 diabetes mellitus
Antoon H van Lierop, Neveen A. T. Hamdy, Rutger W. van der Meer, Jacqueline T. Jonker, Hildo J. Lamb, Luuk J. Rijzewijk, Michaëla Diamant, Johannes Anthonius Romijn, Johannes W. A. Smit, Socrates E. Papapoulos · 2012 · European Journal of Endocrinology
Fracture Risk in Type 2 Diabetes: Current Perspectives and Gender Differences
Giuseppina Tiziana Russo, Annalisa Giandalia, Elisabetta Lucia Romeo, Nunziata Morabito, Marco Muscianisi, Maria Concetta Ruffo, Antonino Catalano, Domenico Cucinotta · 2016 · International Journal of Endocrinology
Structural basis for specific ligation of the peroxisome proliferator-activated receptor δ
Chyuan-Chuan Wu, Thomas J. Baiga, Michael Downes, James J. La Clair, Annette R. Atkins, Stephane B. Richard, Weiwei Fan, T.A. Stockley-Noel, Marianne E. Bowman, Joseph P. Noel et al. · 2017 · Proceedings of the National Academy of Sciences
Diabetes, bone and glucose-lowering agents: clinical outcomes
Ann V. Schwartz · 2017 · Diabetologia
Thiazolidinediones increase the wingless-type MMTV integration site family (WNT) inhibitor Dickkopf-1 in adipocytes: a link with osteogenesis
Birgit Gustafson, Björn Eliasson, Ulf Smith · 2009 · Diabetologia
Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
Mohammad Adil, Rashid Ali Khan, Abul Kalam, Shiva Kumar Venkata, Amit Dattatraya Kandhare, Pinaki Ghosh, Manju Sharma · 2017 · Pharmacological Reports
The current role of thiazolidinediones in diabetes management
Christos V. Rizos, Anastazia A. Kei, Moses Elisaf · 2016 · Archives of Toxicology
Bone metabolism and fracture risk in type 2 diabetes mellitus [Review]
Toru Yamaguchi, Toshitsugu Sugimoto · 2011 · Endocrine Journal
Sulfonylureas and Risk of Falls and Fractures: A Systematic Review
Kate L. Lapane, Shibing Yang, Monique J. Brown, Rachel Jawahar, Caleb Pagliasotti, Swapnil N. Rajpathak · 2013 · Drugs & Aging
Secondary osteoporosis: Pathophysiology & diagnosis
Gregory R. Emkey, Sol Epstein · 2014 · Best Practice & Research Clinical Endocrinology & Metabolism
Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
Ofri Mosenzon, Cheryl Wei, Jaime A. Davidson, Benjamin M. Scirica, Ilan Yanuv, Aliza Rozenberg, Boaz Hirshberg, Avivit Cahn, Christina Stahre, Krzysztof Strojek et al. · 2015 · Diabetes Care
Testosterone supplementation and bone parameters: a systematic review and meta-analysis study
Giovanni Corona, Walter Vena, Alessandro Pizzocaro, Vito Angelo Giagulli, Davide Francomano, Giulia Rastrelli, Gherardo Mazziotti, Antônio Aversa, Andrea Maria Isidori, Rosario Pivonello et al. · 2022 · Journal of Endocrinological Investigation
An Empirical Approach to Explore the Relationship Between Measures of Disproportionate Reporting and Relative Risks from Analytical Studies
Miguel Angel Maciá, Francisco José de Abajo, Gilly Roberts, Jim Slattery, Bharat T. Thakrar, Antoni F. Z. Wisniewski · 2015 · Drug Safety
Rosiglitazone and Outcomes for Patients With Diabetes Mellitus and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial
Richard G. Bach, Maria M. Brooks, Manuel Lombardero, SAUL M. GENUTH, Thomas W. Donner, Alan J. Garber, Laurence Kennedy, Ernest Scott Monrad, Rodica Pop‐Busui, Sheryl F. Kelsey et al. · 2013 · Circulation
Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats.
C. Sedlinsky, M. S. Molinuevo, A. Cortizo, M. J. Tolosa, Juan I. Felice, M. L. Sbaraglini, L. Schurman, A. D. McCarthy · 2011 · European Journal of Pharmacology
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
Rosaria Vincenza Giglio, Νικόλαος Παπάνας, Ali Abbas Rizvi, Marcello Ciaccio, Angelo Maria Patti, Ιoannis Ilias, Anca Pantea Stoian, Amirhossein Sahebkar, Andrej Janež, Manfredi Rizzo · 2022 · Medicina
PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity
Jessal J. Patel, O. Butters, Timothy R. Arnett · 2014 · Cell Biochemistry and Function
Combining GLP ‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
Jens Juul Holst, Tina Vilsbøll · 2012 · Diabetes Obesity and Metabolism
Sitagliptin and risk of fractures in type 2 diabetes: R esults from the TECOS trial
Robert G. Josse, Sumit R. Majumdar, Yinggan Zheng, Amanda Adler, Mary Angelyn Bethel, John B. Buse, Jennifer B. Green, Keith D. Kaufman, Helena W. Rodbard, Tsvetalina I. Tankova et al. · 2016 · Diabetes Obesity and Metabolism
Metformin use and risk of fracture: a systematic review and meta-analysis of observational studies
Asma Salari-Moghaddam, Omid Sadeghi, Ammar Hassanzadeh Keshteli, Bagher A. Larijani, Ahmad Esmaillzadeh · 2019 · Osteoporosis International
Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options
Ching‐Ju Chiu, Ye‐Fong Du, Horng‐Yih Ou, Elizabeth Ann Beverly · 2014 · Clinical Interventions in Aging
Risk of Fractures with Glitazones
Michael Bodmer, Christian Meier, MARIUS E. KRAENZLIN, Christoph Rudolf Meier · 2009 · Drug Safety
Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management
William T. Cefalu, John B. Buse, Stefano Del Prato, Philip Home, Derek LeRoith, Michael Albrecht Nauck, Itamar Raz, Julio Rosenstock, Matthew C. Riddle · 2014 · Diabetes Care
PPARs in Bone: The Role in Bone Cell Differentiation and Regulation of Energy Metabolism
Beata Lecka‐Czernik · 2010 · Current Osteoporosis Reports
Risk of fractures and diabetes medications: a nationwide cohort study
Hyung Jin Choi, C. Park, Young‐Kyun Lee, Yong‐Chan Ha, Sunmee Jang, Chan Soo Shin · 2016 · Osteoporosis International
TZDs and Bone: A Review of the Recent Clinical Evidence
Ann V. Schwartz · 2008 · PPAR Research
Benzimidazolones: A New Class of Selective Peroxisome Proliferator-Activated Receptor γ (PPARγ) Modulators
Weiguo Liu, Fiona WaiYu Lau, Kun Liu, Harold B. Wood, Gaochao Zhou, Yuli Chen, Ying Li, Taro E. Akiyama, Gino A. Castriota, Monica Einstein et al. · 2011 · Journal of Medicinal Chemistry
Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents
Lalit S. Doshi, Manoja Kumar Brahma, Umakant Ashok Bahirat, Amol V. Dixit, Kumar V.S. Nemmani · 2010 · Expert Opinion on Investigational Drugs
Diabetes and Osteoporosis
G. Isanne Schacter, William Donald Leslie · 2021 · Endocrinology and Metabolism Clinics of North America
Thiazolidinediones induce osteocyte apoptosis and increase sclerostin expression
Guillaume Mabilleau, Aleksandra Mieczkowska, MICHAEL E. EDMONDS · 2010 · Diabetic Medicine
Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
Jipan Xie, Madhav A. Namjoshi, Eric Qiong Wu, Kejal Parikh, Melissa D. Diener, Andrew Peng Yu, Amy X. Guo, Kenneth W. Culver · 2011 · Journal of Managed Care Pharmacy
Optimal therapy of type 2 diabetes: a controversial challenge
Angela Dardano, Giuseppe Penno, Stefano Del Prato, Roberto Miccoli · 2014 · Aging
The Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes
Edward W. Lipkin, Ann V. Schwartz, Andrea Anderson, Cralen Davis, Karen Johnson, Edward W. Gregg, George A. Bray, Robert I. Berkowitz, Anne L. Peters, Amelia Hodges et al. · 2014 · Diabetes Care
Diabetes, falls and fractures
D. Mayne, N. R. Stout, Terry Aspray · 2010 · Age and Ageing
Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes
Jakob Starup‐Linde, Søren Gregersen, Morten Frost, Peter Vestergaard · 2016 · Bone
PPARG in osteocytes controls sclerostin expression, bone mass, marrow adiposity and mediates TZD-induced bone loss
Sudipta Baroi, Piotr J. Czernik, Amit Chougule, Patrick R. Griffin, Beata Lecka‐Czernik · 2021 · Bone
Increased Bone Turnover in Type 2 Diabetes Patients Randomized to Bariatric Surgery Versus Medical Therapy at 5 Years
Crawford, Megan R., Pham, Natha n., Khan, Leil a., Bena, James F., Schauer, Philip R., Kashyap, Sangeeta R. · 2018 · Endocrine Practice
Complications of Diabetes Therapy
Sarah Dawn Corathers, Shawn Peavie, Marzieh Salehi · 2013 · Endocrinology and Metabolism Clinics of North America
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary
Alan J. Garber, Martin J. Abrahamson, Joshua I. Barzilay, Lawrence Blonde, Zachary T. Bloomgarden, Michael A. Bush, Samuel E. Dagogo-Jack, Michael Davidson, DANIEL F. EINHORN, Jeffrey R. Garber et al. · 2015 · Endocrine Practice
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic Acid (MK-0533): A Novel Selective Peroxisome Proliferator-Activated Receptor γ Modulator for the Treatment of Type 2 Diabetes Mellitus with a Reduced Potential to Increase Plasma and Extracellular Fluid Volume
John J. Acton, Taro E. Akiyama, Ching H. Chang, Lawrence F. Colwell, Sheryl D. Debenham, Thomas W. Doebber, Monica Einstein, Kun Liu, Margaret E. McCann, David E. Moller et al. · 2009 · Journal of Medicinal Chemistry
DHA increases adiponectin expression more effectively than EPA at relative low concentrations by regulating PPARγ and its phosphorylation at Ser273 in 3T3-L1 adipocytes
Jia Song, Li Cheng, Yushan Lv, Yi Zhang, William Kwame Amakye, Limei Mao · 2017 · Nutrition & Metabolism
Disease burden evaluation of fall-related events in the elderly due to hypoglycemia and other diabetic complications: a clinical review
Usman Hammawa Malabu, Venkat Vangaveti, Lee Kennedy · 2014 · Clinical Epidemiology
Safety and Tolerability of the Treatment of Youth-Onset Type 2 Diabetes
TODAY Study Group · 2013 · Diabetes Care
Thiazolidinediones on PPAR γ : The Roles in Bone Remodeling
Wei Wei, Yihong Wan · 2011 · PPAR Research
Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?
Matteo Tacelli, Ciro Celsa, Bianca Magro, Aurora Giannetti, Grazia Pennisi, Federica Spatola, Salvatore Petta · 2018 · Pharmaceuticals
Osteoblast-targeted overexpression of PPARγ inhibited bone mass gain in male mice and accelerated ovariectomy-induced bone loss in female mice
Sun Wook Cho, Jae‐Yeon Yang, Sun Ju Her, Hyung Jin Choi, Ju Yeon Jung, Hyun Jin Sun, Jee Hyun An, Hwa Young Cho, Sang Wan Kim, Kyong Soo Park et al. · 2011 · Journal of Bone and Mineral Research
Peroxisome Proliferator-Activated Receptor-γ Receptor Ligand Partially Prevents the Development of Endometrial Explants in Baboons: A Prospective, Randomized, Placebo-Controlled Study
Dan I. Lebovic, Jason Mathiu Mwenda, Daniel C. Chai, Alessandro Santi, Xiao Xu, Thomas M. D’Hooghe · 2010 · Endocrinology
Diabetes and the Female Reproductive System
Anindita A. Nandi, Leonid Poretsky · 2013 · Endocrinology and Metabolism Clinics of North America
Real-world antidiabetic drug use and fracture risk in 12,277 patients with type 2 diabetes mellitus: a nested case–control study
Eladio Losada, Berta Soldevila, Mohammed Sanni Ali, Daniel Martínez-Laguna, Xavier Nogués, Manel Puig‐Domingo, Adolfo Díez‐Pérez, Dı́dac Mauricio, Daniel Prieto‐Alhambra · 2018 · Osteoporosis International
Effects of Pioglitazone on Bone in Postmenopausal Women With Impaired Fasting Glucose or Impaired Glucose Tolerance: A Randomized, Double-Blind, Placebo-Controlled Study
Bone, Henry G., Lindsay, Robert, McClung, Michael R., Perez, Alfonso T., Raanan, Marsha G., Spanheimer, Robert G. · 2013 · The Journal of Clinical Endocrinology & Metabolism
Skeletal Fragility in Type 2 Diabetes Mellitus
Jakob Starup‐Linde, Katrine Hygum, Bente Lomholt Langdahl · 2018 · Endocrinology and Metabolism
Discovery of INT131: A selective PPARγ modulator that enhances insulin sensitivity
Joshua P. Taygerly, Lawrence R. McGee, Steven M. Rubenstein, Jonathan B. Houze, Timothy D. Cushing, Yang Li, Alykhan S. Motani, Jinlong Chen, Walter P. Frankmoelle, Guosen Ye et al. · 2012 · Bioorganic & Medicinal Chemistry
NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population
Stefano Ciardullo, Emanuele Muraca, Francesca Zerbini, Giuseppina Manzoni, Gianluca Perseghin · 2021 · The Journal of Clinical Endocrinology & Metabolism
ORIGINAL ARTICLE: Effects of rosiglitazone on bone mineral density and remodelling parameters in Postmenopausal diabetic women: a 2‐year follow‐up study
Zehra Berberoğlu, Ayşe Canan Yazıcı, Nilgün Güvener Demirağ · 2010 · Clinical Endocrinology
The effect of alogliptin and pioglitazone combination therapy on various aspects of β-cell function in patients with recent-onset type 2 diabetes
Daniël H. van Raalte, Renate E. van Genugten, Björn Eliasson, Diane L. Möller-Goede, Andrea Mari, Andrea Tura, Craig Wilson, Penny R. Fleck, Marja‐Riitta Taskinen, Ulf Smith et al. · 2014 · European Journal of Endocrinology
n-3 polyunsaturated fatty acids stimulate osteoclastogenesis through PPARγ-mediated enhancement of c-Fos expression, and suppress osteoclastogenesis through PPARγ-dependent inhibition of NFkB activation
Atsuko Nakanishi, Ikuyo Tsukamoto · 2015 · The Journal of Nutritional Biochemistry
Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36‐month clinical trial
Paola Portillo-Sánchez, Fernando Bril, Romina Lomonaco, Diana Barb, Beverly Orsak, Jan Bruder, Kenneth J. Cusi · 2018 · Journal of Diabetes
Diagnosis and Management of Osteoporosis
Robert W. Lash, Jane M. Nicholson, Lourdes Vélez, R. Van Harrison, Jane McCort · 2009 · Primary Care Clinics in Office Practice
The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial
Grey, Andrew, Bolland, Mark, Fenwick, Sheryl, Horne, Anne, Gamble, Greg, Drury, Paul L, Reid, Ian R · 2014 · European Journal of Endocrinology
Associations with fracture in patients with diabetes: a nested case–control study
Jakob Starup‐Linde, Søren Gregersen, Peter Vestergaard · 2016 · BMJ Open
Rhodium( iii )-catalyzed regioselective C2-amidation of indoles with N-(2,4,6-trichlorobenzoyloxy)amides and its synthetic application to the development of a novel potential PPARγ modulator
Jingjing Shi, Guanguan Zhao, Xiaowei Wang, H. Eric Xu, Wei Yi · 2014 · Organic & Biomolecular Chemistry